Depo-Provera and Meningioma Risk: What Women Need to Know About the 150 mg Dose and Emerging Litigation

Link Between High-Dose Birth Control Injections and Brain Tumors Spurs Legal Action Nationwide

By Anthony Mancini, Mancini Law Group P.C.

Depo-Provera (medroxyprogesterone acetate) is a widely prescribed injectable contraceptive that offers a convenient alternative to daily birth control pills. However, growing evidence has linked extended use of the 150 mg dose of Depo-Provera to the development of meningiomas—a type of brain tumor that can have serious, even life-altering, consequences. As litigation against the manufacturers of Depo-Provera unfolds, women who received repeated injections may now have legal recourse.

Understanding Depo-Provera and the 150 mg Dose

The standard Depo-Provera shot contains 150 milligrams of medroxyprogesterone acetate, a synthetic version of the hormone progesterone. Administered every 12 to 13 weeks, this intramuscular injection is designed to suppress ovulation and prevent pregnancy. It is most commonly marketed under the brand name Depo-Provera CI and is also available in generic versions manufactured by:

• Pharmacia & Upjohn Company LLC (a Pfizer subsidiary)

• Greenstone LLC

• A-S Medication Solutions

• Prasco Laboratories

• Preferred Pharmaceuticals Inc.

  
  

While Depo-Provera has been used safely by many women, studies have now raised serious concerns about the cumulative hormonal exposure resulting from repeated 150 mg injections—especially in women who received four or more doses over a 12-month period.

Meningioma: A Serious Risk Linked to High-Dose, Long-Term Use

Meningiomas are tumors that form in the meninges—the protective membranes surrounding the brain and spinal cord. Although often benign, meningiomas can become dangerous depending on their size and location. Symptoms may include:

• Headaches

• Vision problems

• Memory loss or confusion

• Seizures

• Weakness or numbness

  
  

Recent research suggests that women exposed to prolonged high levels of synthetic progesterone, such as through the 150 mg Depo-Provera injection, may face a significantly higher risk of developing intracranial meningiomas, particularly if the tumors are progesterone receptor-positive.

This connection has prompted regulatory scrutiny overseas. In France, for example, health officials issued a safety warning and updated product labels to reflect the risk of meningioma in patients who received repeated 150 mg injections of Depo-Provera.

Legal Action and the Basis for Litigation

Many women who have developed meningiomas after using Depo-Provera long-term are now filing lawsuits. Allegations include:

• Failure to adequately warn patients and physicians about the risk

• Negligent marketing of a drug with known hormonal risks

• Concealment of safety data from the public and medical community

  
  

These cases often center on patients who received at least 600 mg of medroxyprogesterone acetate (four 150 mg doses) over a 12-month period or longer, leading to significant hormone accumulation and heightened tumor risk.

How Mancini Law Group P.C. Can Help

Our firm is currently reviewing claims from women who:

• Received at least four 150 mg Depo-Provera injections

• Used the drug continuously for 12 months or more

• Were diagnosed with a meningioma following that use

At Mancini Law Group P.C., we bring over 30 years of experience in complex personal injury and pharmaceutical litigation. We understand the devastating impact a brain tumor diagnosis can have—and we fight to secure justice for those harmed by corporate negligence.

Compensation May Include:

• Medical expenses (surgery, imaging, neurology consults)

• Loss of income or earning potential

• Pain and suffering

• Long-term disability or neurological impairment

Schedule a Free Consultation

If you or someone you love was diagnosed with a meningioma after receiving repeated Depo-Provera 150 mg injections, we encourage you to act now. Call 773-745-1909 or visit www.mancinilaw.com